Skip to contentL
Lyell Immunopharma, Inc.
L
LYELLyell Immunopharma, Inc. Q4 2023 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$13.00K$13.00Kderived−100.0% vs Q4 2022 Net Income-$52.93M-$52.93MderivedN/M vs Q4 2022 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lyell Immunopharma, Inc. · CIK 1806952 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$59,508,000N/M Operating Cash Flowderived-$40,635,000N/M Free Cash Flowderived-$40,660,000N/M Margins · derivedOperating margin-457753.8%−457723.3 pt vs Q4 2022
Net margin-407153.8%−407136.5 pt vs Q4 2022
ended Dec 31, 2023 · filed Feb 28, 2024 · 59 d after period end